{"name":"Lindenhofgruppe AG","slug":"lindenhofgruppe-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BACTROBAN® Nasal ong","genericName":"BACTROBAN® Nasal ong","slug":"bactroban-nasal-ong","indication":"Eradication of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA)","status":"marketed"}]}],"pipeline":[{"name":"BACTROBAN® Nasal ong","genericName":"BACTROBAN® Nasal ong","slug":"bactroban-nasal-ong","phase":"marketed","mechanism":"Mupirocin is a topical antibiotic that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase.","indications":["Eradication of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA)","Prevention of staphylococcal nasal colonization"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}